Gene Editing, CRISPR & Synthetic Biology — Applications, Ethics & India's Policy

Gene editing — particularly CRISPR-Cas9 — has transformed biology in a decade from a laboratory tool into approved human therapies, making it among the most examined science-technology topics in UPSC GS3. It combines cutting-edge science with deep ethical, regulatory, and equity questions that the exam frequently probes.

1. DNA and Genetic Basics — A Brief Recap

• DNA (Deoxyribonucleic acid): The molecule carrying genetic instructions; composed of four nucleotide bases — Adenine (A), Thymine (T), Guanine (G), Cytosine (C)
• Gene: A specific sequence of DNA that codes for a protein
• Genome: The complete set of DNA in an organism; the human genome has approximately 3 billion base pairs and ~20,000–25,000 protein-coding genes
• Mutation: A change in the DNA sequence; can cause disease (e.g., sickle cell disease — a single base-pair substitution) or be neutral

Why gene editing matters: Many serious diseases — sickle cell anaemia, haemophilia, beta-thalassaemia, certain cancers, hereditary blindness — result from specific, identifiable genetic errors. The ability to precisely correct these errors is the promise of gene editing.

2. History of Gene Editing Technologies

3. CRISPR-Cas9 — Mechanism

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a natural immune system found in bacteria, which they use to recognise and cut the DNA of invading viruses.

Scientists harnessed and simplified this system for gene editing:

1. Guide RNA (gRNA): A short, synthetic RNA strand designed to match the exact DNA sequence to be edited; acts as a "GPS" to guide the Cas9 protein to the right location in the genome
2. Cas9 protein: Functions as "molecular scissors" — an endonuclease enzyme that cuts both strands of the DNA double helix at the target site
3. DNA repair: After the cut, the cell attempts to repair the break:
   • NHEJ (Non-Homologous End Joining): Imprecise; often introduces small insertions/deletions (indels) that disable the gene — useful for gene knock-out
   • HDR (Homology-Directed Repair): If a repair template is provided, allows precise substitution — useful for gene correction

Advanced variants:

• Base editing: Chemically converts one DNA base to another (e.g., A to G) without cutting the double strand — more precise, fewer off-target effects
• Prime editing: Described as a "search-and-replace" for the genome; uses a reverse transcriptase to write new genetic information; fewer off-target effects than original CRISPR-Cas9

4. Nobel Prize in Chemistry 2020

The 2020 Nobel Prize in Chemistry was jointly awarded to:

• Emmanuelle Charpentier (born 1968, France; Director, Max Planck Unit for the Science of Pathogens, Berlin)
• Jennifer A. Doudna (born 1964, USA; Professor, University of California, Berkeley)

"For the development of a method for genome editing."

They were the first two women to jointly win a Nobel Prize in the sciences. Their key contribution: in 2012, they published a landmark paper showing how CRISPR-Cas9 could be programmed with a guide RNA to cut any target DNA sequence — the invention that launched the modern gene-editing era.

5. Types of Gene Editing — Somatic vs Germline

This is the most important conceptual distinction for UPSC:

6. Key Milestones in Gene Therapy

Casgevy (Exagamglogene Autotemcel): The world's first approved CRISPR-based therapy.

• Approved by FDA: 8 December 2023
• Indication: Sickle cell disease (and later beta-thalassaemia) in patients aged 12 and older with recurrent vaso-occlusive crises
• How it works: Patient's blood stem cells are extracted, edited using CRISPR-Cas9 to reactivate fetal haemoglobin (HbF) production, then reinfused
• Results: In a clinical trial, 29 of 30 patients who could be evaluated were free of severe pain episodes for at least 12 consecutive months
• Developers: Vertex Pharmaceuticals and CRISPR Therapeutics

Other gene therapy milestones:

• LUXTURNA: AAV-based gene therapy for a rare inherited retinal dystrophy (RPE65 mutation) causing blindness; approved by FDA 2017
• Haemophilia B treatments: Gene therapies delivering functional copies of the clotting factor IX gene
• CAR-T cell therapy: Not CRISPR, but a form of gene therapy — immune cells are genetically engineered to target cancer cells; approved for certain leukaemias and lymphomas

7. The He Jiankui Affair — Germline Editing Controversy

The most consequential ethics controversy in modern biotechnology:

• November 2018: Chinese scientist He Jiankui announced — at the Second International Summit on Human Genome Editing in Hong Kong — that he had produced the world's first gene-edited babies
• What he did: He recruited couples where the father was HIV-positive; edited human embryos using CRISPR-Cas9 to disable the CCR5 gene (the protein HIV uses to enter cells), aiming to make the children resistant to HIV
• The babies: Twin girls born in October 2018 (pseudonyms Lulu and Nana); a third gene-edited baby was reportedly born later from the same experiment
• Global condemnation: The scientific community worldwide condemned the experiment as premature, dangerous, and ethically unjustifiable — HIV-positive parenthood can be managed without editing embryos; the CCR5 deletion may have other health consequences
• Legal outcome: On 30 December 2019, a Shenzhen court convicted He Jiankui of "illegal medical practice" and sentenced him to 3 years in prison and a fine of 3 million yuan (~US$430,000). He was released in April 2022.

Why this matters for UPSC: The case crystallised global concern about unilateral germline gene editing and triggered renewed calls for international governance frameworks.

8. Agricultural Applications of CRISPR

CRISPR is increasingly applied in agriculture, creating a distinct regulatory challenge (are CRISPR-edited crops "GMOs"?):

ICAR (Indian Council of Agricultural Research): India's primary agricultural research body is conducting CRISPR research on rice and wheat varieties for disease resistance and improved nutritional profiles.

9. Synthetic Biology

Synthetic biology goes beyond editing existing organisms — it involves designing and constructing new biological parts, devices, and systems, or redesigning existing natural biological systems.

Applications of synthetic biology:

• Biosensors: Bacteria engineered to detect pollutants, pathogens, or landmines in soil
• Living medicines: Engineered gut bacteria that detect and treat colorectal cancer
• Biofuels: Yeast and bacteria engineered to convert cellulose to ethanol more efficiently
• Biomanufacturing: Engineered microorganisms producing pharmaceuticals (insulin, artemisinin for malaria)
• Biological computers: DNA-based logic gates for ultra-dense data storage

10. Gene Drives — Ecological Risk and Promise

A gene drive is a CRISPR-based system designed to propagate a genetic change through an entire wild population much faster than normal Mendelian inheritance would allow (potentially spreading through a population in 10–20 generations).

Potential applications:

• Eliminating malaria by making mosquito populations (Anopheles gambiae) infertile or resistant to Plasmodium
• Controlling invasive species on islands

Risks:

• A gene drive released into a wild population cannot be recalled
• Ecological consequences of eliminating or radically altering a wild species are unpredictable
• Cross-border spread — a gene drive released in one country could spread globally
• Potential for misuse as a bioweapon

Gene drives are governed under the Cartagena Protocol on Biosafety (2000), a supplementary protocol to the Convention on Biological Diversity (CBD), though specific gene drive regulations are still evolving internationally.

11. India's Regulatory Framework

Regulatory challenge for CRISPR crops:

• Traditional GMOs involve inserting DNA from another species — clearly defined as "transgenic"
• CRISPR edits can be made without inserting foreign DNA, making the edited organism genetically indistinguishable from a naturally occurring mutant
• Many countries (USA, Japan, Argentina) exempt certain CRISPR edits from full GMO regulation; India's regulatory framework is still evolving on this question

Cartagena Protocol on Biosafety (2000): India is a signatory; governs the movement of Living Modified Organisms (LMOs) — primarily targeted at transgenic crops but increasingly discussed in the context of gene drives and synthetic biology.

12. Ethical Dimensions

Exam Strategy

For Prelims:

• Nobel Prize Chemistry 2020 = Jennifer Doudna + Emmanuelle Charpentier = CRISPR
• Casgevy = FDA approved December 2023 = first CRISPR therapy = sickle cell disease
• He Jiankui = 2018 = edited CCR5 gene = HIV resistance = 3 years prison = first gene-edited babies
• GEAC = under MoEFCC (not DBT — a common error)
• Cartagena Protocol = biosafety = under CBD

For Mains (GS3):

Questions typically ask: "Discuss applications and ethical concerns of CRISPR" or "What regulatory framework should govern gene editing in India?"

Useful structure:

1. What is CRISPR — brief mechanism (gRNA + Cas9)
2. Applications: somatic therapy (Casgevy), agriculture, synthetic biology
3. Controversies: He Jiankui, germline editing, gene drives
4. India's framework (GEAC, RCGM, DBT) and gaps
5. Way forward: international governance, equity in access, precautionary principle

Key distinction to always mention: Somatic (not heritable, ethically acceptable) vs germline (heritable, ethically controversial) gene editing.

Previous Year Questions (PYQs)

Prelims

• UPSC 2022: With reference to CRISPR-Cas9 technology, which of the following statements is/are correct?
• UPSC 2021: Consider the following: In which of these areas is CRISPR-Cas9 technology being used? (Agriculture, medicine, forensics)
• UPSC 2019: The Nobel Prize in Chemistry 2018 was for which breakthrough? (Directed evolution — different from 2020, important to not confuse)
• UPSC 2018: What is 'gene drive'? (Definition and potential applications)

Mains

• UPSC GS3 2023: "Gene editing technologies hold transformative promise but require robust governance frameworks." Discuss with reference to CRISPR and India's regulatory mechanisms.
• UPSC GS3 2021: What are the applications of gene-editing technology in medicine and agriculture? Examine the ethical and regulatory challenges in the Indian context.
• UPSC GS3 2019: Discuss the potential and limitations of CRISPR-Cas9 as a tool for treating genetic diseases. What ethical concerns does germline editing raise?
• UPSC GS3 2017: "Synthetic biology could be as disruptive as the digital revolution." Evaluate this claim in the context of India's biotechnology sector.